Table 1.

Clinical and Laboratory Characteristics of Human Immunodeficiency Virus (HIV)–infected Infants Whose Mothers Started Highly Active Antiretroviral Therapy (HAART) Postpartum

Variable	Infants included in the analysisa (n=37)	Infants not included in the analysis (n=22)	Pb
Maternal CD4+ cell count at delivery, median cells/mL (IQR)	186 (103, 221) (n=33)	215 (105, 266) (n=21)	.59c
Maternal HIV load at delivery, median log10 copies/mL (IQR)	4.93 (4.60–5.29) (n=33)	4.57 (4.30–5.21) (n=18)	.19c
Maternal sdNVP exposure	25 (67.6)	15 (68.2)	>.99
Infant HIV-infected at the visit where the mother first reported HAART use	33 (89.2)	17 (77.3)	.27
Infant HIV-infected in utero	17 (45.9)	8 (36.4)	.59
Infant HIV-infected by 6 weeks	26 (70.3)	14 (63.6)	.77
Infant regimen			.48
Control	15 (40.5)	11 (50.0)
Extended NVP	8 (21.6)	6 (27.3)
Extended NVP+ZDV	14 (37.8)	5 (22.7)
First visit where the mother reported HAART use
By 3 months	13 (35.1)	6 (27.3)	.57
By 6 months	26 (70.3)	11 (50.0)	.17
Status of infant feeding at the visit where the mother first reported HAART used			.08
Exclusive breastfeeding	22 (59.5)	9 (40.9)
Mixed feeding	10 (27.0)	4 (18.2)
No breastfeeding	5 (13.5)	9 (40.9)

NOTE. Data are no. (%) of infants unless otherwise indicated. IQR, interquartile range; NVP, nevirapine; sdNVP, single-dose nevirapine; ZDV, zidovudine.

^aInfants were included if they had a sample collected within 6 months after the visit where the mother first reported that she was receiving HAART, and if a genotyping result was obtained for that sample.

^bP values are based on Fisher's exact tests, unless otherwise indicated.

^cWilcoxon rank-sum test.

^dIn the Post Exposure Prophylaxis of Infants–Malawi trial, some infants became HIV-infected after the mother reported that she had stopped breastfeeding (unpublished data); therefore, some women are likely to have continued to breastfeed after reporting that they had weaned their infants.